Ferroptosis, mitochondrial stress and redox imbalance: a pharmacological-toxicological biochemistry framework for precision drug therapeutics
Résumé
Ferroptosis, mitochondrial stress and redox imbalance are increasingly recognised as interconnected determinants of therapeutic efficacy, drug resistance and organ toxicity. Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation and impaired antioxidant defences, with relevance to cancer, cardiovascular disease, inflammatory disorders, ischaemia-reperfusion injury and drug-induced tissue damage. This Perspective reframes the ferroptosis-mitochondrial stress-redox axis as a unified pharmacological-toxicological platform rather than an isolated therapeutic target, resolving its mechanisms to individual electron transport chain complexes, membrane phospholipid species and downstream immunological consequences. Beyond the conventional GPX4-system Xc − NRF2 framework, we incorporate dihydroorotate dehydrogenase (DHODH), GCH1-BH4 signalling, NCOA4-mediated ferritinophagy and p53-dependent regulation of ferroptosis sensitivity. We further define how complex I- and III-derived superoxide, compartmentalised inner-membrane lipid pools and ACSL4/LPCAT3-directed phospholipid remodelling shape organ-specific vulnerability. Because ferroptotic cells release damage-associated molecular patterns whose effects depend on cell death kinetics, immunomodulation is considered a distinct therapeutic opportunity and safety consideration. To consolidate these interacting mechanisms into a single, comprehensible reference, we present an integrated molecular pathway diagram that maps oxidative-stress chemistry, compartment-resolved mitochondrial involvement, lipid-substrate specificity, cell-death execution and kinetics-dependent immunological crosstalk onto their corresponding pharmacological entry points. We propose a tiered biomarker framework, a p53-and biomarker-guided patient stratification strategy, a chemically stratified therapeutic map distinguishing repurposed drugs from experimental compounds, and a conceptual pharmacokinetic-pharmacodynamic framework linking therapeutic and toxic exposure windows. Future research should prioritise biomarker validation, complex-specific mitochondrial functional assays, lipidomic profiling, organ-specific toxicology, tumour-selective delivery systems and pharmacokinetic-pharmacodynamic integration to advance safer, more precise ferroptosis-based therapeutics.
Citer ce document
Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)
Accès au document
Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter
Voir l'article sur le site de la revueLicence et provenance
Licence : CC BY
Notice moissonnée depuis OpenAlex le 26/10/2026. Le document reste hébergé par sa source.
Voir le document à la source →